EUVIMEDEUVIMED entdecken
Crossref

Enhancing the Affinity of Novel GLS1 Allosteric Inhibitors By Targeting Key Residue Lys320

Li Zhu, Xiujin Chang, Shengpeng Zhang, Xiumei Bai, Alexander V Finko iD, Xi Xu, Jinlei Bian, Xiaoping Liu, Huidan Huang iD

Future Medicinal Chemistry · 2023

DOI: 10.4155/fmc-2023-0114 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Future Medicinal Chemistry, 2023. Verfasst von Li Zhu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center of Drug Screening & Evaluation, Wannan Medical College, Wuhu, Anhui, 241000, PR China. Hauptthemen laut MEDLINE: Enzyme Inhibitors, Antineoplastic Agents, Lysine, Glutaminase. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

A series of novel GLS1 irreversible allosteric inhibitors targeting Lys320 might have robust enzyme inhibitory activity and potent antitumor activity. Materials & methods: Novel GLS1 allosteric inhibitors targeting Lys320 were synthesized and their anticancer activity was assessed. Moreover, GLS1 protein was used as a model system to analyze the reactivity of these electrophilic groups in GLS1 irreversible allosteric inhibitors with other amino acids, including tyrosine, histidine, serine and threonine, using biochemical and biophysical assays.

Results

AC16 exhibited robust GLS1 inhibitory activity, antiproliferative effect in vitro, good plasma stability and potential covalent addition with GLS1 K320.

Conclusion

This study opens a novel avenue for the design of robust irreversible GLS1 inhibitors targeting the allosteric site K320.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Enzyme InhibitorsAntineoplastic AgentsLysineGlutaminaseHumansAllosteric RegulationStructure-Activity RelationshipCell ProliferationAllosteric SiteCell Line, TumorMolecular Structure

Stichwörter der Autor:innen

GLS1allostericglutamine metabolismirreversiblelysine

Substanzen

Enzyme InhibitorsAntineoplastic AgentsLysineGlutaminase

Autor:innen und Institutionen

  • Center of Drug Screening & Evaluation, Wannan Medical College, Wuhu, Anhui, 241000, PR China.
  • Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, PR China.
  • Department of Chemistry, Lomonosov Moscow State University (MSU), Moscow, 119991, Russia.

ORCID-Profile: Alexander V Finko, Huidan Huang

Zitieren

APA

Zhu, L., Chang, X., Zhang, S., Bai, X., Finko, A. V., Xu, X., Bian, J., Liu, X., & Huang, H. (2023). Enhancing the Affinity of Novel GLS1 Allosteric Inhibitors By Targeting Key Residue Lys320. Future Medicinal Chemistry. https://doi.org/10.4155/fmc-2023-0114

Vancouver

Zhu L, Chang X, Zhang S, Bai X, Finko AV, Xu X, et al. Enhancing the Affinity of Novel GLS1 Allosteric Inhibitors By Targeting Key Residue Lys320. Future Medicinal Chemistry. 2023. doi:10.4155/fmc-2023-0114

BibTeX
@article{Zhu2023,
  author = {Zhu, Li and Chang, Xiujin and Zhang, Shengpeng and Bai, Xiumei and Finko, Alexander V and Xu, Xi and Bian, Jinlei and Liu, Xiaoping and Huang, Huidan},
  title = {Enhancing the Affinity of Novel GLS1 Allosteric Inhibitors By Targeting Key Residue Lys320},
  journal = {Future Medicinal Chemistry},
  year = {2023},
  doi = {10.4155/fmc-2023-0114}
}
Kostenlos starten →